Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Items 701–800 of 1,000
Arsenic-Containing Medicine Treatment Disturbed the Human Intestinal Microbial Flora
Li, J., Chen, X., Zhao, S., & Chen, J. (2023) · Toxics · doi:10.3390/toxics11050458 · Cited by 14
The transcription factor HIF2α partakes in the differentiation block of acute myeloid leukemia
Magliulo, D., Simoni, M., Caserta, C., Fracassi, C., Belluschi, S., Giannetti, K., Pini, R., Zapparoli, E., Beretta, S., Uggé, M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317810 · Cited by 12
Memory effects of prior subculture may impact the quality of multiomic perturbation profiles
Bortel, P., Hagn, G., Skos, L., Bileck, A., Paulitschke, V., Paulitschke, P., Gleiter, L., Mohr, T. T., Gerner, C., & Meier, S. M. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313851121 · Cited by 11
Hecht, A., Nowak, D., Nowak, V., Hanfstein, B., Büchner, T., Spiekermann, K., Weiß, C., Hofmann, W., Lengfelder, E., & Nolte, F. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.08.010 · Cited by 11
“Furthermore, the talian–German APL0406 trial showed that a chemotherapy-free pproach consisting of ATRA plus ATO in induction and consolidaion therapy was not inferior but less toxic, and thus probably even uperior, as compared to approaches including chemotherapy in atients with low and intermediate risk APL [3].”
ResultOptimal approach for high-risk acute promyelocytic leukemia
Iland, H. J., Seymour, J. F., & Wei, A. H. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000025 · Cited by 11
Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia
Lucena-Araujo, A. R., Pereira‐Martins, D. A., Koury, L. C. A., Franca-Neto, P. L., Coelho‐Silva, J. L., Wagatsuma, V. M. D. D., Melo, R. A. M., Bittencourt, R., Pagnano, K. B. B., Pasqüini, R., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017005926 · Cited by 11
Self-citationYu, J. C., Guo, X., Bai, Y., Yang, J., Zheng, X., Ruan, J., & Chen, Z. (2018) · Oncology Reports · doi:10.3892/or.2018.6521 · Cited by 11
“The combined therapy of ATRA and arsenic trioxide (ATO), which eliminates APL by activating PML-RAR α degradation, demonstrates efficacy as an APL therapy and markedly improves the prognosis of patients with APL (4).”
FusionPathway: Prediction of pathways and therapeutic targets associated with gene fusions in cancer
Wu, C.-C., Beird, H. C., Zhang, J., & Futreal, P. A. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006266 · Cited by 12
Giansanti, M., Gabrieli, A. D., Prete, S. P., Ottone, T., Divona, M. D., Karimi, T., Ciccarone, F., Voso, M. T., Graziani, G., & Faraoni, I. (2021) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.121.000537 · Cited by 12
Self-citationTherapeutic approaches to haematological malignancies in adolescents and young adults
Place, A. E., Frederick, N. N., & Sallan, S. E. (2013) · British Journal of Haematology · doi:10.1111/bjh.12556 · Cited by 11
Spezza, E. G., Brethon, B., Petit, A., Mazingue, F., Gandemer, V., Boissel, N., Carausu, L., Réguerre, Y., Leverger, G., & Ducassou, S. (2019) · British Journal of Haematology · doi:10.1111/bjh.16364 · Cited by 11
“Temporary cessation of ATRA and/or ATO is indicated for severe cases (Lo-Coco et al., 2013).”
BackgroundUnexpected Discoveries Should Be Reconsidered in Science—A Look to the Past?
Foletti, A., & Fais, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163973 · Cited by 13
“Some new anti-tumor strategies are taking place based on anti-oxidant treatments, such as the use of retinoic acid [104] or ascorbic acid [105] in the treatment of patients with leukemia and lymphomas; more recently, preclinical in vivo evidence has shown that daily treatment with fermented papaya may control the grow…”
BackgroundTang, B., Guo, M., Zhai, Y., Zhang, K., Ni, K., Zhang, Y., & Huang, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05549-1 · Cited by 10
“ATRA is a natural compound with pro-differentiating properties, and has achieved great success in the treatment of acute promyelocytic leukemia by inducing the differentiation of abnormal blasts to normal cells [39].”
BackgroundWhat is the Standard Regimen for Patients with Acute Promyelocytic Leukemia?
Lo‐Coco, F., & Cicconi, L. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0206-5 · Cited by 10
Self-citationAcute promyelocytic leukemia presenting as a paraspinal mass
Shah, N. N., Stonecypher, M., Gopal, P. P., Luger, S. M., Bagg, A., & Perl, A. E. (2016) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0220 · Cited by 10
“More recently, regimens incorporating both ATRA and arsenic trioxide (ATO) have allowed a substantial number of patients to be treated with little or no additional cytotoxic chemotherapy.(4,5) Patients with APL are on average younger than those with non-M3 AML and typically present with cytopenias and signs/symptoms o…”
BackgroundA personalized approach to acute myeloid leukemia therapy: current options
Illangeswaran, R. S. S., Das, S., Paul, D. Z., Mathews, V., & Balasubramanian, P. (2019) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s168267 · Cited by 13
“It was only after 1992 that the combination of all-trans retinoic acid and arsenic trioxide to induce apoptosis and differentiation created a benchmark in the treatment of acute promyelocytic leukemia.(94) Years later, the genomic landscape of AML helped us to understand that somatic mutations carry prognostic importa…”
BackgroundWang, S., Bi, W., Liu, Y., Cheng, J., Sun, W., Wu, G., & Xu, X. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s215786 · Cited by 11
“Apart from these dietary aspects, high-dose ATRA is also given to adult patients to treat acute promyelocytic leukemia (APL).(26) For this purpose, oral administration of high dosage (45 mg/m(2)) of ATRA is conventionally recommended, which results in a median concentration of approximately 1 μM in plasma.”
BackgroundTreatment for relapsed acute promyelocytic leukemia
Yanada, M. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04954-0 · Cited by 10
“Two randomized studies demonstrated the superiority of ATRA + ATO over ATRA + chemotherapy [11, 12].”
BackgroundRetinoic acid and proteotoxic stress induce AML cell death overcoming stromal cell protection
Liccardo, F., Śniegocka, M., Tito, C., Iaiza, A., Ottone, T., Divona, M., Travaglini, S., Mattei, M., Cicconi, R., Miglietta, S., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02793-z · Cited by 11
“RA-resistant or relapsed patients are effectively treated with a combination of RA and ATO, which mechanism of action is based on its ability to generate oxidative stress thus mediating efficient PML-RARα degradation [18, 20].”
BackgroundInfluentialSelf-citationSchlenk, R. F., Weber, D., Krzykalla, J., Kindler, T., Wulf, G. G., Hertenstein, B., Salih, H. R., Südhoff, T., Krauter, J., Martens, U. M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41964-y · Cited by 10
“Patients with the following disease entities were excluded: AML with t(8;21)(q22;q22.”
BackgroundSelf-citationXu, L., Zeng, Z., Zhang, W., Ren, G., Ling, X., Huang, F., Xie, P., Su, Y., Zhang, X.-K., & Zhou, H. (2017) · Oncotarget · doi:10.18632/oncotarget.14812 · Cited by 10
“ATRA is a widely used and effective clinical drug for APL [32, 33].”
BackgroundThe most novel of the novel agents for acute myeloid leukemia
Perl, A. E. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000411 · Cited by 10
New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A
Fuertes, M., Tkatch, J., Rosmino, J., Nieto, L., Guitelman, M. A., & ARZT, E. S. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00262 · Cited by 13
“Some groups have reported antitumorigenic effects for retinoids in several malignant diseases: epithelial tumors (68), cutaneous malignant diseases (69, 70), Kaposi’s sarcoma (71, 72), squamous cell carcinomas (73, 74), cutaneous T-cell lymphoma (75, 76), neuroblastoma (77), lung cancer (78), acute promyelocytic leuke…”
BackgroundIland, H. J. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.07.004 · Cited by 10
Acute Myeloid Leukemia in Adults
Versluis, J., Cornelissen, J. J., Craddock, C., Sanz, M. Á., Canaani, J., & Nagler, A. (2018) · Springer eBooks · doi:10.1007/978-3-030-02278-5_69 · Cited by 12
Huang, X., Yang, Y., Zhu, D., Zhao, Y., Wei, M., Li, K., Zhu, H., & Zheng, X. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04358-3 · Cited by 12
“The combination of ATRA with As2O3 or chemotherapy dramatically improves the prognosis of APL patients [9].”
BackgroundApplication of Rotational Thromboelastometry in Patients with Acute Promyelocytic Leukemia
Sabljić, N., Pantić, N., Virijević, M., Bukumirić, Z., Novakovic, T., Pravdić, Z., Rajic, J., Vidović, A., Suvajdžić, N., Jaradeh, M., et al. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221119809 · Cited by 11
Teng-Fei, S., Abuduaini, D., Hong-Ming, Z., Chen, X., Wang, W., Zhao, Y.-B., Xiao-Jing, L., Cheng, W., & Shen, Y. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101522 · Cited by 10
AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells
Bing, S., Xiang, S., Xia, Z., Wang, Y., Guan, Z., Che, J., Xu, A., Dong, X., Cao, J., Yang, B., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.024 · Cited by 12
High Cutoff Membrane to Reduce Systemic Inflammation Due to Differentiation Syndrome: A Case Report
Villa, G., Zaragoza, J. J., Sharma, A., Chelazzi, C., Ronco, C., & Gaudio, A. R. D. (2014) · Blood Purification · doi:10.1159/000369379 · Cited by 10
Xu, Z., & Huang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586004 · Cited by 11
“It has been reported that 35%-47% of non-high-risk adults develop leucocytosis after chemotherapy-free induction therapy, while 24% develop leucocytosis after ATRA plus chemotherapy induction (5, 25, 39, 47).”
BackgroundSTAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
Rozovski, U., Harris, D., Li, P., Liu, Z., Jain, P., Manshouri, T., Veletić, I., Ferrajoli, A., Bose, P., Thompson, P. A., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27884 · Cited by 11
“For example, arsenic trioxide, known for its activity in acute promyelocytic leukemia [33], was recently found to inhibit the transcription of GLI1 [34] and induce apoptosis of CLL cells [35].”
BackgroundMicrogranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype
McDonnell, M. H., Smith, E. T., Lipford, E. H., Gerber, J. M., & Grunwald, M. R. (2016) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2015.12.004 · Cited by 10
“The incorporation of arsenic trioxide (ATO) into APL treatment regimens has further increased remission rates and cure rates in APL, while decreasing toxicity [5].”
BackgroundNellessen, C. M., Janzen, V., Mayer, K. T., Giovannini, G., Gembruch, U., Brossart, P., & Merz, W. M. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4583-6 · Cited by 10
“We immediately proceeded with the first consolidation cycle of ATRA in combination with arsenic trioxide (ATO) (according to the APL 04-06-trial) [4].”
MethodBassan, R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8907 · Cited by 10
Nanomedicine strategies to counteract cancer stemness and chemoresistance
Liu, H., Liu, M., Zhao, Y., & Mo, R. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00157 · Cited by 11
Gill, H., Raghupathy, R., Hou, H., Tsai, X. C.-H., Tantiworawit, A., Ooi, M. G. M., Gan, G. G., Wong, C. L., Yim, R., Chin, L., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014999 · Cited by 12
“9,11,50 Conversely, the reduced use of chemotherapy in the ATO groups, particularly the oral-AAA group, resulted in a higher frequency of leukocytosis and, consequently, APL-DS.”
Trama, A., Geerdes, E. E., Demuru, E., Angelis, R. D., Karim-Kos, H. E., Troussard, X., Bennett, D., Marcos‐Gragera, R., Kuehni, C. E., Liu, H., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115336 · Cited by 9
Investigation into biased signaling, glycosylation, and drug vulnerability of acute myeloid leukemia
Pienkowski, T., Golonko, A., Bołkuń, Ł., Wawrzak-Pienkowska, K., Szczerbiński, Ł., Kretowski, A. J., Ciborowski, M., Lewandowski, W., Priebe, W., & Świsłocka, R. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108848 · Cited by 10
Damaj, N., Elias, N., Zeidan, T., & Kattan, J. G. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01556-1 · Cited by 9
“Furthermore, in situations where white blood cell (WBC) counts rise rapidly during induction, there is a heightened risk of DS, warranting temporary discontinuation of ATO to reduce inflammatory complications [33, 34].”
Leech, M., Morris, L. E., Stewart, M., Smith, B. D., Bashey, A., Holland, K., Solomon, S. R., Zhang, X., Carraway, H. E., Pratz, K. W., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.11.001 · Cited by 9
“A landmark report published by the Italian Group demonstrated the efficacy of differentiating therapy alone in the treatment of patients with low- to intermediate-risk APL.(8) Their regimen, although completely eliminating the risk of anthracycline-induced cardiomyopathy, requires approximately 5 months longer to comp…”
InfluentialAcute Promyelocytic Leukemia: Do We Have a New Front-Line Standard of Treatment?
Sanz, M. Á., Iacoboni, G., & Montesinos, P. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0339-z · Cited by 9
“A recently reported randomized, phase 3, multicenter trial from GIMEMA, the German–Austrian Acute Myeloid Leukemia Study Group, and Study Alliance Leukemia [32] has compared for the first time conventional ATRA therapy plus chemotherapy with ATRA therapy plus ATO therapy in patients with APL, but this comparison was r…”
BackgroundRecurrent Arterial and Venous Thromboemboli as Initial Presentation of Acute Promyelocytic Leukemia
Trottier-Tellier (2014) · Journal of Clinical Medicine Research · doi:10.14740/jocmr1864w · Cited by 9
“The natural evolution of APL is very aggressive with median survival of less than 1 month, but recent advances in therapy with combined treatment of ATRA and arsenic provide excellent response with complete remission up to 90-95% of patients [10].”
Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia
Angelis, F. D., & Breccia, M. (2015) · Rare Cancers and Therapy · doi:10.1007/s40487-015-0013-8 · Cited by 9
“Further studies have widened the molecular knowledge around APL pathogenesis and have also demonstrated that arsenic trioxide (ATO) exhibits a significant antileukemic effect in relapsed and low-/ intermediate-risk newly diagnosed patients [12, 13, 15].”
BackgroundMethodSelf-citationJosa‐Culleré, L., Madden, K. S., Cogswell, T. J., Jackson, T., Carter, T. S., Zhang, D., Trevitt, G. P., Davies, S. G., Vyas, P., Wynne, G. M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00574 · Cited by 9
Patel, S. A. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2224473 · Cited by 9
Infante, J. B., Esteves, G. V., Raposo, J., & de Lacerda, J. F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05422-z · Cited by 10
“ED is commonly defined as death occurring within 30 days of APL diagnosis, and its incidence rate ranges from 0 to 8% in clinical trials [2, 3] to 29–32% in real-world registries [4, 5].”
BackgroundHemorrhage in acute promyelocytic leukemia—fibrinolysis in focus
Sabljić, N., Thachil, J. V., Pantić, N., & Mitrović, M. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102499 · Cited by 12
“It should be mentioned that study population consisted only of patients with low-or intermediate-risk APL [28].”
BackgroundIf it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide
Adashek, J. J., Munoz, J. L., & Kurzrock, R. (2024) · Med · doi:10.1016/j.medj.2024.11.003 · Cited by 9
Shin, D., Gong, J., Jeong, S. K., Cho, Y.-W., Kim, H., Kim, T., & Cho, K. (2025) · Advanced Science · doi:10.1002/advs.202412503 · Cited by 16
Salmen, A., Gold, R., & Chan, A. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12258 · Cited by 9
Liu, Y., He, P., Liu, F., Zhou, N.-C., Cheng, X., Shi, L., Zhu, H., Zhao, J., Wang, Y., & Zhang, M. (2014) · Tumor Biology · doi:10.1007/s13277-013-1452-1 · Cited by 9
Rock, N. M., Mattiello, V., Judas, C., Huezo-Diaz, P., Bourquin, J., Gumy‐Pause, F., & Ansari, M. (2014) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2013.876470 · Cited by 9
Kojima, M., Ogiya, D., Ichiki, A., Hara, R., Amaki, J., Kawai, H., Numata, H., Sato, A., Miyamoto, M., Suzuki, R., et al. (2016) · Leukemia Research Reports · doi:10.1016/j.lrr.2016.01.001 · Cited by 9
Chen, J., Cheng, J. J., Yi, J., Xie, B., Lin, L., Liu, Z., Zhao, H.-S., Wang, B., Ai, Z., Yang, Y., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.10.003 · Cited by 9
Castelli, G., Pelosi, E., & Testa, U. (2016) · International Journal of Hematologic Oncology · doi:10.2217/ijh-2016-0011 · Cited by 9
Incident adverse events following therapy for acute promyelocytic leukemia
Kim, P. G., Bridgham, K., Chen, E. C., Vidula, M. K., Pozdnyakova, O., Brunner, A. M., & Fathi, A. T. (2018) · Leukemia Research Reports · doi:10.1016/j.lrr.2018.05.001 · Cited by 9
“Therapeutic regimens were grouped according to common APL backbones and categorized as a) ATRA+ATO-based per gruppo Italiano malattie ematologiche dell'adulto (GIMEMA) [2], b) ATRA+anthracycline+ATO-based per cancer and leukemia group B (CALBG) 9710 [3], c) ATRA+ anthracycline+mitoxantrone-based per programa para el t…”
MethodStem cell damage after chemotherapy- can we do better?
Tang, J., Zhu, N., Rao, S., & Carlson, K.-S. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.001 · Cited by 9
Schultz, M., Blackburn, P. R., Cogbill, C. H., Pitel, B. A., Smadbeck, J. B., Johnson, S. H., Vasmatzis, G., Rech, K. L., Sukov, W. R., Greipp, P. T., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1699081 · Cited by 9
“Acute promyelocytic leukemia (APL) is a time-critical hematologic neoplasm that is amenable to targeted therapy [1].”
BackgroundArsenic Trioxide Treatment during Pregnancy for Acute Promyelocytic Leukemia in a 22-Year-Old Woman
Cochet, C., Simonet, M. B., Cattin, J., Metz, J., Berceanu, A., Deconinck, É., Daguindau, É., Schillinger, F., Fenaux, P., Mottet, N., et al. (2020) · Case Reports in Hematology · doi:10.1155/2020/3686584 · Cited by 10
Kumar, S., & Tchounwou, P. B. (2021) · Environmental Toxicology · doi:10.1002/tox.23299 · Cited by 9
Redner, A., & Kessel, R. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821671-2.00039-8 · Cited by 13
Shi, H., Gao, L., Zhang, W., & Jiang, M. (2022) · BMC Bioinformatics · doi:10.1186/s12859-022-04841-5 · Cited by 9
“differentiation of leukemic promyelocytes in the treatment of acute promyelocytic leukemia [29].”
BackgroundZhang, X., Wu, S., Yang, J., Zhang, G., Su, Y., Zhang, M., He, J., Shi, Y., Li, W., Lu, P., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03507-5 · Cited by 9
Lv, Y., Liu, C., Wang, H., Wang, W., Zhu, M., & Geng, Q. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s92486 · Cited by 9
“Although chemofree induction and consolidation therapy using ATRA/ATO in Lo Cocco’s NEJM paper acquire surprising results, the follow-up time is not very long.(13) This regimen was indeed proven to be a very effective and convenient therapy regimen with lower toxicity compared with most therapy regimens reported previ…”
ADACHI, K., Honma, Y., Miyake, T., Kawakami, K., Takahashi, T., & Suzumiya, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3348 · Cited by 9
Gianni’, M., Fratelli, M., Bolis, M., Kurosaki, M., Zanetti, A., Paroni, G., Rambaldi, A., Borleri, G., Rochette‐Egly, C., Terao, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10556 · Cited by 10
Self-citationAkute Promyelozyten-Leukämie: Neue Behandlungsstrategien mit ATRA und ATO – AML-BFM-Empfehlungen
Creutzig, U., Dworzak, M. N., Neuhoff, N. V., Rasche, M., & Reinhardt, D. (2018) · Klinische Pädiatrie · doi:10.1055/a-0750-5963 · Cited by 9
“[14] Lo-Coco F, Avvisati G, Vignetti M et al.”
BackgroundInfluentialMostaghim, A., Dhanani, M., & Ingalls, R. R. (2019) · SAGE Open Medical Case Reports · doi:10.1177/2050313x19834425 · Cited by 9
Yang, S., Ma, R., Yuan, X., Jiang, L., Shi, J., Yang, J., Lei, P., Zang, Y., Chen, X., Zhang, Y., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.10.003 · Cited by 9
Min, G. J., Cho, B., Park, S., Park, S., Jeon, Y., Yahng, S., Shin, S.-H., Yoon, J., Lee, S., Eom, K., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04010-9 · Cited by 9
Jabbar, N., Khayyam, N., Arshad, U., Maqsood, S., Hamid, S. A., & Mansoor, N. (2021) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-021-01404-1 · Cited by 9
Arsenic trioxide in pediatric cancer – a case series and review of literature
Abele, M., Müller, S.-L., Schleicher, S., Hartmann, U., Döring, M., Queudeville, M., Lang, P., Handgretinger, R., & Ebinger, M. (2021) · Pediatric Hematology and Oncology · doi:10.1080/08880018.2021.1872748 · Cited by 9
Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia
Freyer, C. W., Peterson, C. E., Man, Y., Przespolewski, A., Baron, J. I., & Luger, S. M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1838507 · Cited by 9
NPM1 mutation reprograms leukemic transcription network via reshaping TAD topology
Lai, Q., Hamamoto, K., Luo, H., Zaroogian, Z., Zhou, C., Lesperance, J., Zha, J., Qiu, Y., Guryanova, O. A., Huang, S., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01942-9 · Cited by 10
Katerndahl, C. D. S., Rogers, O. R. S., Day, R. B., Xu, Z., Helton, N., Ramakrishnan, S. M., Miller, C. A., & Ley, T. J. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317690121 · Cited by 8
Potential of fat-soluble vitamins as a platform for antiviral drug development
Hirota, Y., Okamoto, M., Baba, M., & Suhara, Y. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130292 · Cited by 8
Tang, F., Lu, S., Zhao, X., Qin, Y., Liu, X., Jia, J., Wang, J., Gong, L., Jiang, Q., Zhao, T., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17752 · Cited by 9
“Data from our nearly 54-month follow-up period showed that EFS and OS of ATRA plus arsenic for non-high-risk APL at 5 years were 92 3% and 96 3% respectively, which was comparable to the results of prior studies.(1,2,9) Notably, in the present study, the percentage of oral arsenic (83 3%) was significantly higher than…”
BackgroundResultInfluentialNguyen, É., Richerolle, A., Sánchez-Bellver, J., Varennes, J., & Ségal-Bendirdjian, E. (2022) · Biomedicines · doi:10.3390/biomedicines10030695 · Cited by 9
“We focused the analysis on two different regulatory regions of the hTERT gene previously analyzed in APL cells [30]: the first region (region I) of the hTERT promoter extended from −650 to + 150 bp relative to the transcription start site (TSS), the second region (region II), the hTERT-5 kb region, located far upstrea…”
BackgroundInfluentialAll-trans retinoic acid increases the pathogenicity of the H9N2 influenza virus in mice
Niu, X., Wang, H., Zhao, L., Lian, P., Bai, Y., Li, J., & Qiao, J. (2022) · Virology Journal · doi:10.1186/s12985-022-01809-y · Cited by 9
“In addition, ATRA is also applied for the prevention and treatment of different types of cancers [21, 22], particularly the acute promyelocytic leukemia (APL), which has achieved great success treated by ATRA combined with chemotherapeutic agents [23, 24].”
BackgroundMethodDennis, M., Copland, M., Kaur, H., Kell, J., Nikolousis, E., Mehta, P., Palanicawandar, R., Potter, V. T., Raj, K. K., Thomas, I., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18369 · Cited by 8
Srinivasan, S., Dhamne, C. A., Moulik, N. R., Chichra, A., Tembhare, P. R., Patkar, N. V., Subramanian, P. G., Shetty, D. L., Narula, G., & Banavali, S. D. (2023) · The Indian Journal of Pediatrics · doi:10.1007/s12098-023-04689-4 · Cited by 8
“https://doi.org/10.1007/s12098-023-04689-4 differentiating agents, all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) [ 1 , 2 ].”
InfluentialWu, D., & Gao, R. (2023) · Hematology · doi:10.1080/16078454.2023.2227495 · Cited by 8
“More than 98% of patients with APL have a promyelocytic leukemia – retinoic acid receptor alpha (PML::RARA) fusion gene caused by the chromosomal translocation t (15; 17) (q22; q21), which is sensitive to therapy with ATRA and arsenic trioxide (ATO) therapy[1,2].”
BackgroundBai, W., Liu, D., Cheng, Q., Yang, X., Zhu, L., Qin, L., & Fang, J. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101850 · Cited by 10
Can arsenic do anything good? Arsenic nanodrugs in the fight against cancer – last decade review
Komorowicz, I., & Hańć, A. (2024) · Talanta · doi:10.1016/j.talanta.2024.126240 · Cited by 8
Hennig, D., Müller, S., Wichmann, C. W., Drube, S., Pietschmann, K., Pelzl, L., Grez, M., Bug, G., Heinzel, T., & Krämer, O. H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.589 · Cited by 10
“Of note, clinically successful ATRA/arsenic trioxide combinations also synergise in PML-RARa elimination and apoptosis, but they do not enhance differentiation (Nasr et al, 2009; Lo-Coco et al, 2013).”
BackgroundNakamura, D., Yoshimitsu, M., Kuroki, A., Hachiman, M., Kamada, Y., Chibueze, C. E., Arai, A., Inoue, H., 浜田平一郎, Hayashida, M., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.06.303 · Cited by 9
“PBMCs (5 10) from a patient with chronic ATL Discussion In comparison to other cancers, the prognosis for patients with hematologic malignant diseases has greatly improved owing to recent advances in intensive chemotherapy and molecular targeted therapy treatment options [16–18].”
BackgroundXu, W., Liu, S., Wu, D., Qiao, G., & Yan, J. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438525 · Cited by 8
Martinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 9
Kumar, M., Vineetha, R., & Kudva, A. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.024 · Cited by 8
Hickey, E., Clemons, B., Griffin, S. P., Cox, J. N., Sutphin, S. D., Ramlal, R., & Benitez, L. L. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1639163 · Cited by 8
“patients with baseline QTc >450ms and cardiac conditions is not always translated to clinical practice, less stringent parameters may contribute to cardiac adverse effects [4].”
BackgroundJAMY, O. H., Godby, R. C., Dhir, A., Costa, L. J., & Xavier, A. C. (2021) · Cancer · doi:10.1002/cncr.33593 · Cited by 8
Patel, S. A. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215579 · Cited by 8
Rongvaux-Gaïda, D., Dupuis, M., Poupon, J., Djebrani‐Oussedik, N., Lemonnier, C., & Rieger, F. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.07.004 · Cited by 8
Zhao, J., Wang, W., Li, Y., Chen, X., Li, W., Li, W., Chen, T., & Chen, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1011023 · Cited by 8
“The hallmark of classic APL is the fusion gene and chimeric protein of promyelocytic leukemia and retinoic acid receptor-a (PML-RARA) caused by chromosome translocation t(15;17)(q24;q21) (1).”
BackgroundThrun, M. C., Mack, E., Neubauer, A., Haferlach, T., Frech, M., Ultsch, A., & Brendel, C. A. (2022) · Bioengineering · doi:10.3390/bioengineering9110642 · Cited by 8
“One of these clusters is APL, the only subclass of AML that has been previously defined, and is managed therapeutically differently from all other AML subclasses in the clinic [72].”
BackgroundArsenic trioxide rewires mantle cell lymphoma response to bortezomib
Zhao, L., Liu, Y., Peng, L., Fei, A., Cui, W., Miao, S., Hermine, O., Gressin, R., Khochbin, S., Chen, S., et al. (2015) · Cancer Medicine · doi:10.1002/cam4.511 · Cited by 8
“ATO used to be a second- line treatment for relapsed or refractory APL; however, it has gradually become the firstline choice in newly diagnosed APL [39, 40].”
InfluentialLachaîne, J., Mathurin, K., Barakat, S., & Schuh, A. C. (2014) · Hematological Oncology · doi:10.1002/hon.2176 · Cited by 8
“To our knowledge, this is the first economic evaluation conducted in APL.”
BackgroundMethodResultInfluentialZhong, L., Wang, Y., Li, W., Gu, J., Li, X., Wang, X., Yue, Z., Mu, Y., Bai, J., Li, R., et al. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2027-1 · Cited by 8
Akute Leukämien des Erwachsenen
Eigendorff, E., & Hochhaus, A. (2015) · Der Pathologe · doi:10.1007/s00292-015-0087-y · Cited by 8
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.